Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors

被引:66
作者
Demirer, Taner [1 ]
Barkholt, Lisbeth [3 ]
Blaise, Didier [11 ]
Pedrazzoli, Paolo [4 ]
Aglietta, Massimo [5 ]
Carella, Angelo Michele [6 ]
Bay, Jacques-Olivier [9 ]
Arpaci, Fikret [2 ]
Rosti, Giovanni [7 ]
Gurman, Gunhan [1 ]
Niederwieser, Dietger [10 ]
Bregni, Marco [8 ]
机构
[1] Ankara Univ, Sch Med, Dept Haematol Oncol, TR-06100 Ankara, Turkey
[2] Ankara Univ, Sch Med, Dept Med Oncol, TR-06100 Ankara, Turkey
[3] Karolinska Univ, Huddinge Hosp, Huddinge, Sweden
[4] Osped Niguarda Ca Granda, Falck Div Med Oncol, Milan, Italy
[5] Inst Canc Res & Treatment, Turin, Italy
[6] Azienda Osped Univ San Martino, Div Ematol, Genoa, Italy
[7] Osped Reg, Treviso, Italy
[8] Ist Sci San Raffaele, Dept Oncol, Strateg Program Oncol, I-20132 Milan, Italy
[9] Ctr Jean Perrin CHU Clermont Ferrand, Federat Greffe Moelle & Therapie Cellulaire Auver, Clermont Ferrand, France
[10] Univ Hosp Leipzig, Div Hematol Oncol, Leipzig, Germany
[11] Inst Paoli Calmettes, Marseille, France
来源
NATURE CLINICAL PRACTICE ONCOLOGY | 2008年 / 5卷 / 05期
关键词
allogeneic stem-cell transplantation; graft-versus-host; graft-versus-tumor; immunotherapy; renal cell carcinoma (RCC);
D O I
10.1038/ncponc1104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Allogeneic transplantation of hematopoietic cells from an HLA-compatible donor has been used to treat hematologic malignancies. Allogeneic transplantation not only replaces the marrow affected by the disease, but exerts an immune graft-versus-tumor (GVT) effect mediated by donor lymphocytes. The development of nonmyeloablative conditioning regimens before allogeneic transplantation has allowed this therapy to be used in elderly and disabled patients. An allogeneic GVT effect is observed in a proportion of patients with renal, breast, colorectal, ovarian, and pancreatic cancer treated with allogeneic transplantation. In general, the tumor response is associated with the development of acute and chronic graft-versus-host disease. Further improvements will depend on the identification of the antigen targets of GVT, and on reduction of the toxicity of the procedure. Targeted therapies may complement the immune effect of allogeneic transplantation. We present updated results from the literature and data recently placed on file at the European Bone Marrow Transplantation Solid Tumors Working Party.
引用
收藏
页码:256 / 267
页数:12
相关论文
共 86 条
  • [61] Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
    Niederwieser, D
    Maris, M
    Shizuru, JA
    Petersdorf, E
    Hegenbart, U
    Sandmaier, BM
    Maloney, DG
    Storer, B
    Lange, T
    Chauncey, T
    Deininger, M
    Pönisch, W
    Anasetti, C
    Woolfrey, A
    Little, MT
    Blume, KG
    McSweeney, PA
    Storb, RF
    [J]. BLOOD, 2003, 101 (04) : 1620 - 1629
  • [62] Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
    Omuro, Y
    Matsumoto, G
    Sasaki, T
    Tanaka, Y
    Maeda, Y
    Sakamaki, H
    Hiruma, K
    Tsuruta, K
    Takahashi, T
    [J]. BONE MARROW TRANSPLANTATION, 2003, 31 (10) : 943 - 945
  • [63] Tumor-infiltrating T-cells - Friend or foe of neoplastic cells?
    Parmiani, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (25) : 2640 - 2641
  • [64] Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation
    Peccatori, J
    Barkholt, L
    Demirer, T
    Sormani, MP
    Bruzzi, P
    Ciceri, F
    Zambelli, A
    Da Prada, GA
    Pedrazzoli, P
    Siena, S
    Massenkeil, G
    Martino, R
    Lenhoff, S
    Corradini, P
    Rosti, G
    Ringden, O
    Bregni, M
    Niederwieser, D
    [J]. CANCER, 2005, 104 (10) : 2099 - 2103
  • [65] Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen - A pilot study in patients with refractory malignancies
    Pedrazzoli, P
    Da Prada, GA
    Giorgiani, G
    Schiavo, R
    Zambelli, A
    Giraldi, E
    Landonio, G
    Locatelli, F
    Siena, S
    Della Cuna, GR
    [J]. CANCER, 2002, 94 (09) : 2409 - 2415
  • [66] Porter DL, 1996, BONE MARROW TRANSPL, V18, P975
  • [67] An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes
    Probst-Kepper, M
    Stroobant, V
    Kridel, R
    Gaugler, B
    Landry, C
    Brasseur, F
    Cosyns, JP
    Weynand, B
    Boon, T
    Van den Eynde, BJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (10) : 1189 - 1198
  • [68] Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors
    Re, Francesca
    Staudacher, Carlo
    Zamai, Loris
    Vecchio, Viviana
    Bregni, Marco
    [J]. CANCER, 2006, 107 (03) : 640 - 648
  • [69] Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: A CALGB Intergroup phase II study
    Rini, BI
    Halabi, S
    Barrier, R
    Margolin, KA
    Avigan, D
    Logan, T
    Stadler, WM
    McCarthy, PL
    Linker, CA
    Small, EJ
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (07) : 778 - 785
  • [70] Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results
    Rini, BI
    Zimmerman, T
    Stadler, WM
    Gajewski, TF
    Vogelzang, NJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2017 - 2024